# Character Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/character-biosciences

- Industry: Biotechnology
- Headquarters: Jersey City, US
- Website: www.characterbio.com
- Total disclosed funding: $75M
- Latest round: Series B (Sep 2, 2025)
- Investors on record: 14

## About

Character Biosciences focuses on precision medicine for polygenic diseases, emphasizing innovative genomic solutions and artificial intelligence to enhance treatment options for age-related macular degeneration and glaucoma.Character Biosciences, founded in 2019 in Jersey City, US, specializes in precision medicine. The company has successfully completed a total of 3 deals, with the most recent occurring on March 25, 2025. Character Biosciences raised USD 93.000 mn in its Series B funding round, co-led by aMoon and Luma Group, along with participation from other notable investors such as Jefferson Health and Bausch & Lomb Optical Company. The founder's details are not specified in the available information.Character Biosciences specializes in precision medicine aimed at treating polygenic diseases, focusing on age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG). Their core offerings involve leveraging advanced genomic databases, clinical data, and artificial intelligence to identify genetic factors influencing disease progression. The company targets healthcare providers, research institutions, and pharmaceutical companies, facilitating enhanced treatment options for these conditions across North America and Europe.Character Biosciences generates revenue through collaborations with healthcare providers, research organizations, and pharmaceutical companies. The firm engages in B2B transactions structured around joint research and the development of proprietary therapies tailored to specific patient demographics. Revenue is derived from strategic partnerships and potential licensing agreements for their therapies, with a focus on scalable solutions that integrate into existing healthcare frameworks. Their ongoing development of the drug pipeline, particularly for AMD treatments, positions them within the ophthalmology sector.In March 2025, Character Biosciences secured USD 93.000 mn in Series B funding, which will be utilized to advance its lead assets for age-related macular degeneration, CTX203 and CTX114, through Phase 1 and Phase 2 trials and to expand its pipeline into other eye diseases. The company is aiming to enhance its presence in existing markets while exploring opportunities in new regions. Details on upcoming product launches are not specified, but the funding is expected to significantly support their strategic initiatives in precision medicine.

## Funding rounds

- Series B, Sep 2, 2025, $8.9M — Sanofi Ventures
- Series B, Mar 20, 2025, $48M — Bausch + Lomb Corporation, Innovation Endeavors, Section 32, aMoon, KdT Ventures, Jefferson Health, Catalio Capital Management, Luma Group
- Series A, May 17, 2022, $18M — Industry Ventures, Innovation Endeavors, Casdin Capital, Clover Health Inc., Cantos Ventures, Section 32, LifeForce Capital, Catalio Capital Management
- Seed, Apr 1, 2020 — Industry Ventures, Casdin Capital, Clover Health Inc., Cantos Ventures, LifeForce Capital

## Investors

- Industry Ventures (https://capitalatlas.ai/funds/industry-ventures) — Seed, Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Seed, Series A
- Clover Health Inc. — Seed, Series A
- Cantos Ventures (https://capitalatlas.ai/funds/cantos-ventures) — Seed, Series A
- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Seed, Series A
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Series A, Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series A, Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A, Series B
- Bausch + Lomb Corporation — Series B
- aMoon (https://capitalatlas.ai/funds/amoon) — Series B
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Series B
- Jefferson Health — Series B
- Luma Group (https://capitalatlas.ai/funds/luma-group) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B